The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Systemic Delivery of Synthetic MicroRNA-16 Inhibits the Growth of Metastatic Prostate Tumors via Downregulation of Multiple Cell-cycle Genes
Open accessAbstract
Recent reports have linked the expression of specific microRNAs (miRNAs) with tumorigenesis and metastasis. Here, we show that microRNA (miR)-16, which is expressed at lower levels in prostate cancer cells, affects the proliferation of human prostate cancer cell lines both in vitro and in vivo. Transient transfection with synthetic miR-16 significantly reduced cell proliferation of 22Rv1, Du145, PPC-1, and PC-3M-luc cells. A prostate cancer xenograft model revealed that atelocollagen could efficiently deliver synthetic miR-16 to tumor cells on bone tissues in mice when injected into tail veins. In the therapeutic bone metastasis model, injection of miR-16 with atelocollagen via tail vein significantly inhibited the growth of prostate tumors in bone. Cell model studies indicate that miR-16 likely suppresses prostate tumor growth by regulating the expression of genes such as CDK1 and CDK2 associated with cell-cycle control and cellular proliferation. There is a trend toward lower miR-16 expression in human prostate tumors versus normal prostate tissues. Thus, this study indicates the therapeutic potential of miRNA in an animal model of cancer metastasis with systemic miRNA injection and suggest that systemic delivery of miR-16 could be used to treat patients with advanced prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
KEGG for linking genomes to life and the environment
Kanehisa, M., Araki, M., Goto, S., Hattori, M., Hirakawa, M., Itoh, M., Katayama, T., Kawashima, S., Okuda, S., Tokimatsu, T., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm882 · Cited by 6,782
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307323101 · Cited by 4,095
Cited by
Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells
Kosaka, N., Iguchi, H., Yoshioka, Y., Takeshita, F., Matsuki, Y., & Ochiya, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.107821 · Cited by 1,934
Self-citationTumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,736
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Kosaka, N., Iguchi, H., Hagiwara, K., Yoshioka, Y., Takeshita, F., & Ochiya, T. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.446831 · Cited by 771
Self-citationmicroRNAs in cancer management
Kong, Y. W., Ferland-McCollough, D., Jackson, T. J., & Bushell, M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70073-6 · Cited by 734
Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34
Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D., & Bader, A. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0655 · Cited by 677
Self-citationTrang, P., Wiggins, J. F., Daige, C. L., Cho, C., Omotola, M., Brown, D., Weidhaas, J. B., Bader, A. G., & Slack, F. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.48 · Cited by 667
Self-citationDevelopment of microRNA therapeutics is coming of age
van Rooij, E., & Kauppinen, S. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201100899 · Cited by 625
The Promise of MicroRNA Replacement Therapy
Bader, A. G., Brown, D., & Winkler, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2010 · Cited by 617
Self-citationZhang, Y., Wang, Z., & Gemeinhart, R. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.015 · Cited by 535
Regression of murine lung tumors by the let-7 microRNA
Trang, P., Medina, P. P., Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Homer, R., Brown, D., Bader, A. G., Weidhaas, J. B., et al. (2010) · Oncogene · doi:10.1038/onc.2009.445 · Cited by 500
Self-citationMicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review
Catto, J. W. F., Alcaraz, A., Bjartell, A. S., De Vere White, R., Evans, C. P., Fussel, S., Hamdy, F. C., Kallioniemi, O., Mengual, L., Schlomm, T., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.01.044 · Cited by 469
Bueno, M. J., & Malumbres, M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.02.002 · Cited by 410
MicroRNAs in neuronal function and dysfunction
Im, H.-I., & Kenny, P. J. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.01.004 · Cited by 399
MicroRNA Replacement Therapy for miR-145 and miR-33a Is Efficacious in a Model of Colon Carcinoma
Ibrahim, A. F., Weirauch, U., Thomas, M., Grünweller, A., Hartmann, R. K., & Aigner, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4645 · Cited by 400
Exosomal miRNAs: Biological Properties and Therapeutic Potential
Hu, G., Drescher, K. M., & Chen, X.-M. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00056 · Cited by 394
Finnerty, J. R., Wang, W.-X., Hébert, S. S., Wilfred, B. R., Mao, G., & Nelson, P. T. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.07.051 · Cited by 371
Developing therapeutic microRNAs for cancer
Bader, A. G., Brown, D., Stoudemire, J., & Lammers, P. (2011) · Gene Therapy · doi:10.1038/gt.2011.79 · Cited by 333
Self-citationRNA-based diagnostic and therapeutic strategies for cardiovascular disease
Lu, D., & Thum, T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0218-x · Cited by 331
MicroRNAs in idiopathic pulmonary fibrosis
Pandit, K. V., Milosevic, J., & Kaminski, N. (2011) · Translational Research · doi:10.1016/j.trsl.2011.01.012 · Cited by 311
Treating cancer with microRNA replacement therapy: A literature review
Hosseinahli, N., Aghapour, M., Duijf, P. H. G., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26514 · Cited by 305
miR-22 represses cancer progression by inducing cellular senescence
Xu, D., Takeshita, F., Hino, Y., Fukunaga, S., Kudo, Y., Tamaki, A., Matsunaga, J., Takahashi, R.-U., Takata, T., Shimamoto, A., et al. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201010100 · Cited by 289
Self-citationDelivering the promise of miRNA cancer therapeutics
Pereira, D. M., Rodrigues, P. M., Borralho, P. M., & Rodrigues, C. M. P. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.002 · Cited by 288
Wang, X. W., Heegaard, N. H. H., & Ørum, H. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.007 · Cited by 280
Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma
Reid, G., Pel, M. E., Kirschner, M. B., Cheng, Y. Y., Mugridge, N., Weiss, J., Williams, M., Wright, C., Edelman, J. J. B., Vallely, M. P., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt412 · Cited by 275
MicroRNA control of epithelial–mesenchymal transition and metastasis
Zhang, J., & Ma, L. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9368-6 · Cited by 273
Osaki, M., Takeshita, F., Sugimoto, Y., Kosaka, N., Yamamoto, Y., Yoshioka, Y., Kobayashi, E., Yamada, T., Kawai, A., Inoue, T., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.53 · Cited by 271
Self-citationJang, J.-Y., Lee, J.-K., Jeon, Y.-K., & Kim, C.-W. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-421 · Cited by 270
Competitive Interactions of Cancer Cells and Normal Cells via Secretory MicroRNAs
Kosaka, N., Iguchi, H., Yoshioka, Y., Hagiwara, K., Takeshita, F., & Ochiya, T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.288662 · Cited by 267
Self-citationMicroRNA replacement therapy in cancer
Mollaei, H., Safaralizadeh, R., & Rostami, Z. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28058 · Cited by 262
Melo, S., Villanueva, A., Moutinho, C., Davalos, V., Spizzo, R., Ivan, C., Rossi, S., Setien, F., Casanovas, O., Simo-Riudalbas, L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014720108 · Cited by 253
MicroRNA as an Important Target for Anticancer Drug Development
Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K. K.-W., & Shi, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.736323 · Cited by 133
The Roles of MicroRNAs in Breast Cancer
Takahashi, R.-U., Miyazaki, H., & Ochiya, T. (2015) · Cancers · doi:10.3390/cancers7020598 · Cited by 116
Self-citationFractionated Radiation Alters Oncomir and Tumor Suppressor miRNAs in Human Prostate Cancer Cells
John-Aryankalayil, M., Palayoor, S. T., Makinde, A. Y., Cerna, D., Simone, C. B., Falduto, M. T., Magnuson, S. R., & Coleman, C. N. (2012) · Radiation Research · doi:10.1667/rr2703.1 · Cited by 75
Dysregulation of the mitogen granulin in human cancer through the miR-15/107 microRNA gene group
Wang, W.-X., Kyprianou, N., Wang, X., & Nelson, P. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1684 · Cited by 48
Verma, P., Ghosh, A., Ray, M., & Sarkar, S. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200310091719 · Cited by 41
Inhibition of miR-21 in glioma cells using catalytic nucleic acids
Belter, A., Rolle, K., Piwecka, M., Fedoruk-Wyszomirska, A., Naskręt-Barciszewska, M. Z., & Barciszewski, J. (2016) · Scientific Reports · doi:10.1038/srep24516 · Cited by 36
Metadata
- Authors
- Takeshita, F., Patrawala, L., Osaki, M., Takahashi, R.-U., Yamamoto, Y., Kosaka, N., Kawamata, M., Kelnar, K., Bader, A. G., Brown, D., & Ochiya, T.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 18
- Issue
- 1
- Pages
- 181-187
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2048577371
- Cited by
- 420
- References
- 32
- FWCI
- 13.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.